TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Profusa ( (PFSA) ) is now available.
On October 30, 2025, Profusa announced its strategic plan to generate $200 to $250 million in revenue by 2030, driven by the commercialization of its Lumee tissue oxygen and glucose monitoring technologies. The company plans to launch its products in the EU by 2026, followed by the US in 2027, with a focus on expanding market coverage and addressing significant unmet medical needs in conditions like peripheral artery disease and diabetes. Profusa’s innovative platform is expected to disrupt the digital health industry by offering a less invasive, cost-effective solution for continuous biochemical monitoring, potentially impacting healthcare systems and insurers positively.
More about Profusa
Profusa, based in Berkeley, California, is a commercial stage digital health company specializing in the development of tissue-integrated sensors for continuous biochemical monitoring. The company aims to provide personalized medical-grade data for both personal and clinical use through its innovative biosensors and intelligent data platform.
Average Trading Volume: 10,454,526
Technical Sentiment Signal: Sell
Current Market Cap: $11.95M
See more insights into PFSA stock on TipRanks’ Stock Analysis page.